Endeavor Private Wealth Inc. Has $237,000 Stake in Pfizer Inc. (NYSE:PFE)

Endeavor Private Wealth Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 969.2% in the first quarter, Holdings Channel reports. The fund owned 9,345 shares of the biopharmaceutical company’s stock after acquiring an additional 8,471 shares during the period. Endeavor Private Wealth Inc.’s holdings in Pfizer were worth $237,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Northern Trust Corp boosted its position in shares of Pfizer by 7.7% during the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after buying an additional 4,167,222 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Pfizer by 3.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock worth $1,045,351,000 after buying an additional 1,333,740 shares during the period. Invesco Ltd. boosted its position in shares of Pfizer by 9.6% during the fourth quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company’s stock worth $781,524,000 after buying an additional 2,579,455 shares during the period. Pacer Advisors Inc. boosted its position in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Finally, Federated Hermes Inc. boosted its position in shares of Pfizer by 22.2% during the first quarter. Federated Hermes Inc. now owns 17,592,709 shares of the biopharmaceutical company’s stock worth $445,799,000 after buying an additional 3,201,087 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research report on Tuesday, April 22nd. BMO Capital Markets dropped their target price on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Berenberg Bank dropped their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Jefferies Financial Group upped their target price on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Wednesday, May 21st. Finally, The Goldman Sachs Group upped their target price on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $28.28.

Pfizer Trading Up 0.9%

Shares of NYSE:PFE opened at $23.49 on Friday. The company has a market capitalization of $133.55 billion, a P/E ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The business’s 50 day simple moving average is $24.36 and its 200 day simple moving average is $24.58.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.82 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.